Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults

Overview of attention for article published in Vaccine, July 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 226 followers.

@elvariant @lucien35499757 Oui effectivement oui... bossez l'argumentaire les gars https://t.co/kzpSZM7sEU

4-7-2022: Researchers in New Zealand report that the BioNTech-invented, BNT162b2 tozinameran Comirnaty COVID-19 vaccine was ineffective against New Zealand's Omicron subvariants: https://t.co/oQXQuC3q5X https://t.co/UEDb0xm3E9 https://t.co/L7DOHpR73c h…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.